Skip to main content
. 2013 Jan 31;2013(1):CD007633. doi: 10.1002/14651858.CD007633.pub2

Kingsley 2009.

Methods This was a multicentre, randomised, double‐blind, placebo‐controlled trial, which lasted 6 months (the MIPA (methotrexate in active psoriatic arthritis) trial).
The trial conducted intention‐to‐treat analysis.
Participants Inclusion criteria of the trial
  • Participants with active psoriatic arthritis

Interventions
  • Oral methotrexate (15 mg/week)

  • Placebo

Outcomes Outcomes of the trial
  1. Improvement of nail score

Notes The trial reported dropouts.
This was a conference publication.